To get delisted, IMUC's share price would have to drop below 1$ per share and stay there for 30 consecutive days. Presently, at 2$ per share, the MC of IMUC is about 80 m$. To drop below 1$ per share would mean that the market values this company at less than 40 m$. With about 30 m$ in cash on the company's accounts after this secondary is closed, you are, in fact, suggesting that the assets of this company could be valued as low as less than 10 m$.
For a biotech, IMUC has quite a nice pipeline of one project in clinical stage development and two in pre-clin, ready to move into the clinics during the first half of next year. Their lead project, ICT-107 for newly diagnosed glioblastoma multiforme (brain cancer) patients, is in a randomized, double-blind, placebo controlled phase II trial, that completed enrollment in early September and is awaiting clinical data in spring next year, autumn at the latest. IMUC having published exceptionally strong efficacy signals from a phase I trial in this indication, and a phase II designed and powered to support early FDA filing for approval if positive in this high-unmet medical need indication, I see battalions of biotechs with much less convincing data and performance plus debt on the balance sheet (nota bene: IMUC is debt free) with a MC 20x or even 30x if not higher than what you see looming for IMUC.
Only a general market crash could take IMUC low enough for long enough to justify your "prophecy", niteowl.